Trigeminal neuralgia

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Trigeminal neuralgia. / Maarbjerg, Stine; Di Stefano, Giulia; Bendtsen, Lars; Cruccu, Giorgio.

I: Cephalalgia : an international journal of headache, Bind 37, Nr. 7, 2017, s. 648-657.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Maarbjerg, S, Di Stefano, G, Bendtsen, L & Cruccu, G 2017, 'Trigeminal neuralgia', Cephalalgia : an international journal of headache, bind 37, nr. 7, s. 648-657. https://doi.org/10.1177/0333102416687280

APA

Maarbjerg, S., Di Stefano, G., Bendtsen, L., & Cruccu, G. (2017). Trigeminal neuralgia. Cephalalgia : an international journal of headache, 37(7), 648-657. https://doi.org/10.1177/0333102416687280

Vancouver

Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia. Cephalalgia : an international journal of headache. 2017;37(7):648-657. https://doi.org/10.1177/0333102416687280

Author

Maarbjerg, Stine ; Di Stefano, Giulia ; Bendtsen, Lars ; Cruccu, Giorgio. / Trigeminal neuralgia. I: Cephalalgia : an international journal of headache. 2017 ; Bind 37, Nr. 7. s. 648-657.

Bibtex

@article{2145a0c797b04390b0a3c1b645cbf0ed,
title = "Trigeminal neuralgia",
abstract = "Introduction Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in one or more divisions of the trigeminal nerve. In addition to the paroxysmal pain, some patients also have continuous pain. TN is divided into classical TN (CTN) and secondary TN (STN). Etiology and pathophysiology Demyelination of primary sensory trigeminal afferents in the root entry zone is the predominant pathophysiological mechanism. Most likely, demyelination paves the way for generation of ectopic impulses and ephaptic crosstalk. In a significant proportion of the patients, the demyelination is caused by a neurovascular conflict with morphological changes such as compression of the trigeminal root. However, there are also other unknown etiological factors, as only half of the CTN patients have morphological changes. STN is caused by multiple sclerosis or a space-occupying lesion affecting the trigeminal nerve. Differential diagnosis and treatment Important differential diagnoses include trigeminal autonomic cephalalgias, posttraumatic or postherpetic pain and other facial pains. First line treatment is prophylactic medication with sodium channel blockers, and second line treatment is neurosurgical intervention. Future perspectives Future studies should focus on genetics, unexplored etiological factors, sensory function, the neurosurgical outcome and complications, combination and neuromodulation treatment as well as development of new drugs with better tolerability.",
author = "Stine Maarbjerg and {Di Stefano}, Giulia and Lars Bendtsen and Giorgio Cruccu",
year = "2017",
doi = "10.1177/0333102416687280",
language = "English",
volume = "37",
pages = "648--657",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "7",

}

RIS

TY - JOUR

T1 - Trigeminal neuralgia

AU - Maarbjerg, Stine

AU - Di Stefano, Giulia

AU - Bendtsen, Lars

AU - Cruccu, Giorgio

PY - 2017

Y1 - 2017

N2 - Introduction Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in one or more divisions of the trigeminal nerve. In addition to the paroxysmal pain, some patients also have continuous pain. TN is divided into classical TN (CTN) and secondary TN (STN). Etiology and pathophysiology Demyelination of primary sensory trigeminal afferents in the root entry zone is the predominant pathophysiological mechanism. Most likely, demyelination paves the way for generation of ectopic impulses and ephaptic crosstalk. In a significant proportion of the patients, the demyelination is caused by a neurovascular conflict with morphological changes such as compression of the trigeminal root. However, there are also other unknown etiological factors, as only half of the CTN patients have morphological changes. STN is caused by multiple sclerosis or a space-occupying lesion affecting the trigeminal nerve. Differential diagnosis and treatment Important differential diagnoses include trigeminal autonomic cephalalgias, posttraumatic or postherpetic pain and other facial pains. First line treatment is prophylactic medication with sodium channel blockers, and second line treatment is neurosurgical intervention. Future perspectives Future studies should focus on genetics, unexplored etiological factors, sensory function, the neurosurgical outcome and complications, combination and neuromodulation treatment as well as development of new drugs with better tolerability.

AB - Introduction Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in one or more divisions of the trigeminal nerve. In addition to the paroxysmal pain, some patients also have continuous pain. TN is divided into classical TN (CTN) and secondary TN (STN). Etiology and pathophysiology Demyelination of primary sensory trigeminal afferents in the root entry zone is the predominant pathophysiological mechanism. Most likely, demyelination paves the way for generation of ectopic impulses and ephaptic crosstalk. In a significant proportion of the patients, the demyelination is caused by a neurovascular conflict with morphological changes such as compression of the trigeminal root. However, there are also other unknown etiological factors, as only half of the CTN patients have morphological changes. STN is caused by multiple sclerosis or a space-occupying lesion affecting the trigeminal nerve. Differential diagnosis and treatment Important differential diagnoses include trigeminal autonomic cephalalgias, posttraumatic or postherpetic pain and other facial pains. First line treatment is prophylactic medication with sodium channel blockers, and second line treatment is neurosurgical intervention. Future perspectives Future studies should focus on genetics, unexplored etiological factors, sensory function, the neurosurgical outcome and complications, combination and neuromodulation treatment as well as development of new drugs with better tolerability.

U2 - 10.1177/0333102416687280

DO - 10.1177/0333102416687280

M3 - Review

C2 - 28076964

VL - 37

SP - 648

EP - 657

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 7

ER -

ID: 193975686